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Abstract
Background: Fluticasone furoate (FF) is a novel long-acting inhaled corticosteroid (ICS). This double-blind, placebo-
controlled randomized study evaluated the efficacy and safety of FF 200 mcg or 400 mcg once daily, either in the
morning or in the evening, and FF 200 mcg twice daily (morning and evening), for 8 weeks in patients with
persistent asthma.
Methods: Asthma patients maintained on ICS for ≥ 3 months with baseline morning forced expiratory volume in
one second (FEV1) 50-80% of predicted normal value and FEV1 reversibility of ≥ 12% and ≥ 200 ml were eligible.
The primary endpoint was mean change from baseline FEV1 at week 8 in pre-dose (morning or evening
[depending on regimen], pre-rescue bronchodilator) FEV1.
Results: A total of 545 patients received one of five FF treatment groups and 101 patients received placebo
(intent-to-treat population). Each of the five FF treatment groups produced a statistically significant improvement
in pre-dose FEV1 compared with placebo (p < 0.05). FF 400 mcg once daily in the evening and FF 200 mcg twice
daily produced similar placebo-adjusted improvements in evening pre-dose FEV1 at week 8 (240 ml vs. 235 ml). FF
400 mcg once daily in the morning, although effective, resulted in a smaller improvement in morning pre-dose
FEV1 than FF 200 mcg twice daily at week 8 (315 ml vs. 202 ml). The incidence of oral candidiasis was low (0-4%)
and UC excretion was comparable with placebo for all FF groups.
Conclusions: FF at total daily doses of 200 mcg or 400 mcg was significantly more effective than placebo. FF 400
mcg once daily in the evening had similar efficacy to FF 200 mcg twice daily and all FF regimens had a safety
tolerability profile generally similar to placebo. This indicates that inhaled FF is an effective and well tolerated once-
daily treatment for mild-to-moderate asthma.
Trial registration: NCT00398645
Keywords: once-daily, ICS, asthma
Background
Despite the availability of effective preventative thera-
pies, asthma remains a major global healthcare problem,
placing a significant burden on healthcare systems,
patients and their families [1,2]. According to the World
Health Organization, approximately 15 million disabil-
ity-adjusted life years are lost annually due to asthma
and approximately 1 in every 250 deaths worldwide are
attributable to the disease [3].
As the cornerstone of anti-inflammatory therapy for
all severities of asthma, inhaled corticosteroids (ICS)
provide a number of benefits including control of
asthma symptoms, improvement in lung function,
decrease in airway hyper-responsiveness [4], reductions
in asthma exacerbations, and reduced asthma mortality
[5,6]. As a reflection of this, the current Global Initiative
for Asthma guidelines recommend an ICS as a first-line
controller therapy for asthma patients of all ages, who
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are not controlled on an as-needed, rapid acting beta2
agonist [2].
Despite comprehensive guidelines, a significant propor-
tion of patients continue to have asthma symptoms that
remain uncontrolled [7,8]. Twenty-four hour coverage
might be expected to provide greater asthma control;
however, the complexity of asthma treatment regimens
and consequent poor adherence to treatment have been
cited as major contributing factors to the current poor
level of global asthma control [2,9,10]. Once-daily treat-
ments offer increased convenience, with the potential for
improved adherence and asthma control [11]. Many of
the commonly prescribed ICS therapies for asthma,
including beclomethasone dipropionate, flunisolide, cicle-
sonide and fluticasone propionate, are indicated for
twice-daily dosing; however, once-daily administration
has been investigated in some ICS including budesonide
[12-14], mometasone furoate [15], and ciclesonide [16].
These studies have indicated that once daily evening
administration is at least as effective as once daily morn-
ing administration with respect to PEF [13], or results in
greater FEV1/FVC [15] or peak expiratory flow (PEF) [16]
with evening versus morning administration. In each of
these studies no difference was seen between once daily
morning or evening administration in terms of AEs [13],
including cortisol levels where assessed [15,16].
Fluticasone furoate (FF) is a novel ICS and is structurally
different to fluticasone propionate (FP). FF has an ester
derived from 2-furoic acid at the C-17a position that
replaces the simpler propionate ester [17]. This feature of
FF confers both greater affinity for and longer retention in
respiratory tissues than FP [18]. FF remains active 24
hours after administration; therefore it is in development
for use as a once-daily inhaled treatment for asthma. Data
from an early phase clinical study demonstrated that the
duration of action of FF extends beyond 24 hours and is
therefore longer than that of FP, making FF potentially
suitable for consideration of once-daily administration
[19]. The program of phase II dose selection studies evalu-
ating FF in asthma is now complete; findings from several
of these trials have shown that FF has a favourable efficacy
and safety profile when administered as a once-daily treat-
ment for asthma [20-22].
This phase II study was designed to compare the effi-
cacy and safety of FF 200 mcg and 400 mcg adminis-
tered once daily in the morning or in the evening, with
FF 200 mcg twice daily (morning and evening) in
patients ≥ 12 years with persistent asthma who
remained symptomatic despite low-dose ICS therapy.
Methods
Study design
This was a phase IIa, randomized, double-blind, parallel-
group, placebo-controlled study conducted at 70
investigative sites in 16 countries around the world (clini-
caltrials.gov study number NCT00398645; GSK study
number FFA106783). The study was conducted between
November 2006 and August 2007 and comprised a 2-
week pre-treatment screening period (Day -14 to Day 0)
for evaluation of eligibility and asthma status, an 8-week
double-blind treatment phase, and telephonic follow-up
contact 1 week after completing the study medication.
During the double-blind treatment phase, patients were
required to attend 5 on-treatment morning clinic visits
(weeks 1, 2, 4, 6, and 8) and 3 on-treatment evening
clinic visits (weeks 2, 4, and 8). Patients were issued with
electronic daily diaries (eDiary; Asthma Monitor plus
[AM 2+], Jaeger, Hoechberg, Germany), which were used
to enter information including morning and evening PEF
(measured using the AM 2+ device), daytime and night-
time asthma symptom score, daytime and night-time use
of salbutamol rescue medication. These data were then
used to establish eligibility during the screening period
and to establish a baseline from which to determine
symptomatic worsening of asthma during the double-
blind treatment period. Patients were also asked to
record in their eDiary their use of non-study issued
maintenance ICS during the screening period and their
use of blinded study medication to assess compliance
with study medication. eDiary data for PEF, rescue medi-
cation and symptom score were not data based or ana-
lyzed and the information collected was used by the
study investigator for safety purposes only. All patients
were assessed and treated on an out-patient basis.
The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines and was approved by local ethics committees
and institutional review boards as appropriate. All
patients provided written informed consent prior to par-
ticipating in the study.
Patients
Male and female patients aged ≥ 12 years with a docu-
mented history of asthma as defined by the National
Institute of Health [2,23] were eligible for study entry.
Other inclusion criteria were baseline morning forced
expiratory volume in one second (FEV1) 50-80% of the
predicted normal value, and reversibility of baseline
FEV1 (≥ 12% and ≥ 200 ml) in response to inhaled sal-
butamol. Study participants had to be able to replace
their current short-acting beta2 agonist (SABA) therapy
with salbutamol inhalation aerosol during the screening
period, and to be able to withhold all inhaled short-act-
ing beta sympathomimetic bronchodilators for 6 hours
before each study visit. They also had to have been tak-
ing ICS for ≥ 3 months before screening, with a stable
daily dose for 4 weeks before screening. The maximum
daily ICS dose was FP 200 mcg or equivalent.
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Patients were excluded if they had a history of life-
threatening asthma, a respiratory infection within 4
weeks of screening, an asthma exacerbation within 4
weeks of screening, or that required oral corticosteroids
within 3 months or hospitalization within 6 months of
screening, clinically significant uncontrolled disease, oro-
pharyngeal candidiasis, or a recent (1 year) or heavy (>
10 pack years) smoking history. Female patients of
childbearing potential who were not using an acceptable
method of contraception and patients with severe milk
protein allergy or an adverse drug reaction to any beta2
agonist, sympathomimetic drug or intranasal, inhaled, or
systemic corticosteroid were also excluded.
After the 2-week screening period, patients were ran-
domized if morning pre-dose FEV1 was 50-80% of the
predicted normal value and within ± 15% of the pre-
bronchodilator FEV1, and if they continued to have
symptoms requiring salbutamol use or a 24-hour asthma
symptom score of ≥ 1 on at least 4 of the last 7 days of
screening. Patients were excluded if during screening
they had changes to their asthma medication, a lower or
upper respiratory tract infection, asthma exacerbation,
oral candidiasis, or were non-compliant with the eDiary.
Study treatment
Patients who successfully completed the screening per-
iod were randomized to one of six treatments (ratio,
1:1:1:1:1:1) administered via a Diskus®/Accuhaler® for 8
weeks: FF 200 mcg or 400 mcg once daily in the morn-
ing, FF 200 mcg or 400 mcg once daily in the evening,
FF 200 mcg twice daily, or placebo (twice daily). Patients
had stopped their usual ICS therapy one day prior to
randomization. Patients who were randomized to once-
daily treatment received a matching placebo Diskus®/
Accuhaler®. Patients were instructed to administer one
inhalation from one inhaler in the morning and one
inhalation from the other inhaler in the evening,
approximately 12 hours apart. Use of the salbutamol
Diskus®/Accuhaler® device or nebulized salbutamol
(excluding for reversibility testing during screening) was
not allowed during the study. The use of a salbutamol
metered-dose inhaler was, however, permitted for symp-
tom relief.
Patients, investigators and study personnel were all
blinded to study treatment. The central randomization
schedule was generated by the sponsor using a validated
computerized system (RandAll). Patients were rando-
mized using Registration and Medication Ordering Sys-
tem (RAMOS), an automated, interactive telephone
based system, which was used by the investigator or
designee to register and randomize the patient and
receive medication assignment information.
Patients were observed by appropriately trained site
personnel during each clinic visit to ensure that they
were able to administer the study drug correctly. The
eDiary was used to question patients on their compli-
ance with study medication each morning and evening;
patients who were not compliant were counselled on
the appropriate way to administer the study drug.
The following anti-asthma medications were not
allowed ≤ 2 weeks before screening or during the study:
combination therapy comprising an inhaled beta2 ago-
nist and ICS, slow-release bronchodilators, anticholiner-
gics, long-acting beta2 agonists (LABA), ketotifen,
nedocromil sodium, sodium cromoglycate, and oral
LABA. Other drugs prohibited before screening included
oral SABA (within 24 hours), anti-leukotrienes or potent
CYP3A4 inhibitors (within 4 weeks), and systemic, oral,
parenteral, or depot corticosteroids, or anti-IgE therapy
(within 3 months). Immunotherapy was permitted if
initiated before screening and used at a stable dose for
the treatment of allergies. Drug therapies for other med-
ical conditions, with the exception of systemic corticos-
teroids, were permitted throughout the study provided
the dose remained constant and their use was not
expected to affect the patient’s lung function or asthma
status.
Efficacy assessment
The primary, single, efficacy endpoint was the mean
change from baseline at week 8 in the pre-dose (morning
or evening [depending on regimen], pre-rescue bronchodi-
lator) FEV1 (measured using a MasterScope CT spirom-
eter [Viasys, Hoechberg, Germany]). This was recorded
electronically at the morning clinic visits between 6 am
and 11 am or at the evening clinic visits between 6 pm
and 11 pm using flow-volume curves generated from cali-
brated spirometers and according to ATS/ERS guidelines
[24]. Patients were required to withhold their salbutamol
therapy for ≥ 6 hours before each clinic visit. Treatment
compliance was derived from the number of positive
answers in the patient’s eDiary, which were divided by the
number of non-missing answers and expressed as a per-
centage for both morning and evening doses.
Safety evaluation
The following safety endpoints were evaluated: inci-
dence of adverse events (AEs) and serious AEs (SAEs),
vital signs, hematology, clinical chemistry, and urinaly-
sis parameters, oropharyngeal examinations, and with-
drawals due to worsening asthma. AEs/SAEs were
coded using the Medical Dictionary for Regulatory
Activities. Twenty-four hour urinary-free cortisol
excretion was also measured at baseline (week 0) and
at the end of the double-blind treatment period (week
8) to assess hypothalamic-pituitary-adrenal axis (HPA)
function. A central laboratory was used for all cortisol
measurements.
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Statistical analysis
Assuming a common standard deviation of 450 ml, a sam-
ple size of 648 patients (108 per group) was required to
provide 90% power to detect a treatment difference of 200
ml in pre-dose FEV1 between FF and placebo at the (two-
sided) 5% significance level. The study was not powered to
formally assess differences between once-daily treatment
and twice-daily treatment or differences between morning
treatment and evening treatment, therefore statistical
comparisons of all FF treatment groups were only against
placebo. However it was pre-specified in the study proto-
col that provided the FF treatment groups demonstrated a
statistically significant difference relative to placebo, the
relative effects of once-daily and twice-daily dosing and of
morning and evening dosing would be evaluated by asses-
sing the degree of overlap between the 95% confidence
intervals relating to the treatment differences with placebo.
If the point estimate of the treatment/placebo difference
for any given FF regimen lay within the 95% confidence
interval for another FF regimen, the treatment effect esti-
mates would be within 0.12 L of each other.
The intent-to-treat (ITT) population, which included
all randomized patients who received at least one dose
of study medication, was the primary population for all
efficacy and safety (excluding urinary cortisol) analyses.
The per protocol (PP) population (all subjects in the
ITT population who did not have any full protocol
deviations) was used for confirmatory analysis of the
primary endpoint.
Analysis of the primary efficacy endpoint was con-
ducted using an analysis of covariance (ANCOVA)
model with effects due to baseline pre-dose FEV1, coun-
try, sex, age, and treatment group. Any patient with a
missing FEV1 measurement at week 8 was included in
the analysis of the primary endpoint by imputation
using the preceding non-missing FEV1 value (last obser-
vation carried forward). The analysis was performed
separately for morning and evening time-points, with
the placebo and twice-daily regimens used in both cases.
Estimated treatment differences for pair-wise compari-
sons against placebo were presented together with 95%
confidence intervals for the difference and p values.
The patient population for urinary cortisol (UC) ana-
lyses comprised all patients whose urine samples were
not considered to have confounding factors that would
affect the interpretation of the results. The 24-hour UC
excretion was log-transformed and analyzed using an
ANCOVA model with effects due to baseline, country,
sex, age, and treatment group.
Results
Patients
A total of 1424 patients were screened with 652 patients
randomized into the study. A total of 646 randomized
patients received at least one dose of study drug and
comprised the ITT population. Of these patients, 101
were assigned to placebo, 105 and 103, respectively,
received FF 200 mcg once daily in the morning or eve-
ning, 111 and 113, respectively, received FF 400 mcg
once daily in the morning or evening, and 113 were
allocated to FF 200 mcg twice daily. The study was
completed by 65 (64%) placebo-treated patients and 455
(83%) FF-treated patients. A total of 597 patients had no
full protocol deviations and therefore comprised the PP
population. Reasons for patient withdrawal at the
screening and randomization stages are summarized in
Figure 1.
All treatment groups were comparable and well
matched with respect to baseline demographic and dis-
ease characteristics (Table 1). Mean age of the study
population overall was 45.1 years, with a higher propor-
tion of females. More than half of the patients (57%)
had at least a 10-year history of asthma and lung func-
tion was similar across all 6 treatment groups.
Treatment compliance during the active treatment
phase was similar across all treatment groups. Mean
overall compliance ranged from 97.4-99.1% and from
96.6-98.4% for the morning and evening dosing regi-
mens, respectively. Mean exposure to study drug was
43.1 days in the placebo group and ranged from 50.3-
52.2 days in the FF groups; exposure was highest in the
FF 400 mcg once-daily morning group and lowest in the
FF 200 mcg once-daily evening group.
Efficacy
There were statistically significant improvements in pre-
dose FEV1 for each FF treatment arm compared with
placebo (Figure 2, Table 2). FF 400 mcg once daily in
the evening resulted in similar placebo-adjusted
improvements in evening pre-dose FEV1 at week 8 com-
pared with FF 200 mcg twice daily (240 ml vs. 235 ml).
FF 200 mcg twice daily resulted in greater improve-
ments in placebo-adjusted morning pre-dose FEV1 than
400 mcg once daily in the morning at week 8 (315 ml
vs. 202 ml).
A ≥ 200 ml increase in placebo-adjusted pre-dose
FEV1 was observed for FF 400 mcg administered once
daily in the morning or evening and for FF 200 mcg
twice daily but not for either of the FF 200 mcg once-
daily dose groups. Nevertheless, increase from baseline
was ≥ 200 ml with both FF 200 mcg once-daily dose
groups. The week 8 AM and PM FEV1 responses for
each treatment are shown in Figure 3.
Because all FF treatments resulted in a significant dif-
ference from placebo the relative effects of once-daily
and twice-daily dosing and of morning and evening dos-
ing were evaluated by assessing the degree of overlap
between the 95% confidence intervals relating to the
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Figure 1 Study design (CONSORT).
Table 1 Baseline characteristics (ITT population)
Demographic Characteristics Placebo
(n = 101)
FF dose
200 mcg OD/AM
(n = 105)
200 mcg OD/PM
(n = 103)
400 mcg OD/AM
(n = 111)
400 mcg OD/PM
(n = 113)
200 mcg
BD
(n = 113)
Female gender, n (%) 62 (61) 62 (59) 74 (72) 73 (66) 70 (62) 78 (69)
Age (years), mean 44.4 45.0 43.7 46.9 45.0 45.6
Race, n (%)†
White 60 (60) 68 (65) 67 (66) 74 (67) 75 (68) 76 (67)
Asian 16 (16) 14 (13) 15 (15) 16 (15) 15 (14) 17 (15)
Other 24 (24) 22 (22) 20 (20) 20 (18) 21 (19) 20 (18)
Asthma history, n (%)
< 1 year 3 (3) 1 (< 1) 3 (3) 2 (2)* 3 (3) 3 (3)*
≥ 1 to < 5 years 16 (16) 12 (11) 19 (18) 14 (13) 19 (17) 17 (15)
≥ 5 to < 10 years 24 (24) 26 (25) 26 (25) 30 (27) 24 (21) 35 (31)
≥ 10 years 58 (57) 66 (63) 55 (53) 65 (59) 67 (59) 58 (51)
Lung function, mean
Pre-bronchodilator FEV1, litres 1.966 1.969 1.986 1.931 1.995 1.976
% predicted FEV1, (%) 66.37 66.52 68.24 67.23 67.69 68.14
% reversibility FEV1, (%) 30.16 29.25 29.29 27.94 30.90 26.32
*1 patient < 6 months
†Data on race unavailable for 6 patients
AM = morning dosing; BD = twice daily; FEV1 = forced expiratory volume in one second; OD = once daily; PM = evening dosing
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Figure 2 Adjusted treatment difference in pre-dose FEV1 (ml) (last observation carried forward; ITT population).
Table 2 Change from baseline in trough FEV1 (litres) (last observation carried forward) at week 8, by evening (PM) vs.
morning (AM) FEV1 and treatment group (ITT population)
Week 8 PM FEV1
Placebo
(n = 101)
FF dose
200 mcg OD/PM
(n = 103)
400 mcg OD/PM
(n = 113)
200 mcg
BD
(n = 113)
Trough FEV1 (n) 77 92 103 100
LS mean (SE) 2.198
(0.0458)
2.322
(0.0437)
2.438
(0.0398)
2.432
(0.0411)
LS mean change (SE) 0.084
(0.0458)
0.208
(0.0437)
0.324
(0.0398)
0.319
(0.0411)
Difference from placebo
Difference 0.124 0.240 0.235
95% CI 0.010, 0.238 0.129, 0.351 0.123, 0.346
p value 0.033 < 0.001 < 0.001
Week 8 AM FEV1
Placebo
(n = 101)
FF dose
200 mcg OD/AM
(n = 105)
400 mcg OD/AM
(n = 111)
200 mcg
BD
(n = 113)
Trough FEV1 (n) 85 100 106 102
LS mean (SE) 2.029 (0.0434) 2.203 (0.0389) 2.230 (0.0397) 2.344 (0.0400)
LS mean change (SE) 0.053
(0.0434)
0.228
(0.0389)
0.255
(0.0397)
0.368
(0.040)
Difference from placebo
Difference 0.174 0.202 0.315
95% CI 0.067, 0.282 0.096, 0.307 0.208, 0.421
p value 0.002 < 0.001 < 0.001
BD = twice daily; CI = confidence interval; FEV1 = forced expiratory volume in one second; FF = fluticasone furoate; LS = least square; OD = once daily; SE =
standard error
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treatment differences with placebo. The point estimate
for the difference from placebo for morning pre-dose
FEV1 for 400 mcg dosed once daily in the morning was
not within the 95% confidence interval for the placebo
adjusted change from baseline in morning FEV1seen
with FF 200 mcg dosed twice-daily (202 ml point esti-
mate for FF 400 mcg OD vs. 208 ml lower 95% confi-
dence interval for FF 200 mcg BD). In contrast the
point estimate for the placebo adjusted change from
baseline in evening FEV1 for 400 mcg once daily in the
evening was within the 95% confidence interval for the
placebo adjusted change from baseline in evening FEV1
seen with FF 200 mcg twice daily, indicating that the
efficacy of FF 400 mcg once daily in the evening is simi-
lar to that of FF 200 mcg twice daily.
Results for the PP population were consistent with
those of the ITT population although the relative treat-
ment effect of all FF treatment groups was generally
lower. The effect of FF 200 mcg once daily dosed in the
evening on pre-dose (evening) FEV1 was not signifi-
cantly different from placebo (p = 0.264).
Safety
The proportion of patients who reported any AE during
the treatment period was 28% in the placebo group and
31-39% in the FF treatment groups. The most frequently
reported AEs during treatment were headache (6-9%),
nasopharyngitis (3-8%), bronchitis (0-4%), pharyngolar-
yngeal pain (< 1-3%), and upper respiratory tract infec-
tion (< 1-3%) (Table 3). The incidence and type of AEs
were generally similar to placebo and the frequency of
AEs did not appear to be related to the dose of FF.
A total of four SAEs were reported. Two of these
occurred on treatment and included one case of angioe-
dema in the FF 200 mcg once-daily evening group and
one case of atrial fibrillation in the FF 400 mcg once-
daily morning group. Two other SAEs were reported
post-treatment and included one case of spontaneous
abortion and one cerebrovascular accident (ischemic
lesion) in two separate patients both in the FF 200 mcg
twice-daily group. All 4 patients required hospitalization
for their SAEs; however, only the case of angioedema
was considered to be possibly related to the study drug.
The patient was subsequently withdrawn from the study
and treated with intravenous hydrocortisone after which
her condition improved with no sequelae.
A total of 11 patients reported 13 AEs that resulted in
study withdrawal: 3 patients in the FF 200 mcg once-
daily morning group, 1 in the FF 200 mcg once-daily eve-
ning group, 3 in the FF 400 mcg once-daily morning
group, 3 in the FF 400 mcg once-daily evening group and
1 in the FF 200 mcg twice-daily group. Two of these
events (angioedema and cerebrovascular accident, already
described) met the criteria for an SAE. Nine of the AEs
were considered by the investigator to possibly be related
to the study drug and included swelling of the eyelids
and lips and increased blood pressure (FF 200 mcg once-
daily morning), acute localized Quincke’s oedema of the
eyes (FF 200 mcg once-daily evening), headache and ele-
vated gamma glutamyl transferase levels (FF 400 mcg
once-daily morning) and oedema, facial rash, and hyper-
sensitivity reaction (FF 400 mcg once-daily evening). No
deaths were reported during the study. There were no
safety concerns related to vital signs, or laboratory safety
tests. No treatment-related changes were apparent. The
incidence of oral candidiasis was low in the FF treatment
groups (0-4% vs. < 1% for placebo) as was the incidence
of asthma exacerbations (< 1-4% vs. 14% for placebo).
24-hour UC excretion at week 8 was similar across
treatment groups with adjusted geometric means of
48.24 nmol/24 hour for placebo and 43.41-57.23 nmol/
24 hour for the FF treatment groups. The adjusted
ratios to baseline were 0.87 for placebo and 0.78-1.03
for the FF treatment groups and the adjusted ratios to
placebo for the FF treatment groups ranged from 0.90-
1.19 (Figure 4).
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Figure 3 Comparison of AM and PM FEV1 at week 8 following once-daily dosing in the evening or morning, or twice-daily dosing (ITT
population).
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Discussion
This study was designed to assess the efficacy and safety
of FF 200 mcg or 400 mcg administered once daily in
the morning or evening and FF 200 mcg administered
twice daily in the morning and evening in patients with
mild to moderate asthma who were still symptomatic
despite treatment with low-dose ICS therapy. FF 400
mcg administered once-daily in the morning or evening
and FF 200 mcg administered twice daily (approximately
12 hours apart) each resulted in clinically and statisti-
cally significant improvements in pre-dose FEV1, as
defined by an increase of ≥ 200 ml, compared with pla-
cebo, after 8 weeks of dosing. Furthermore, FF 400 mcg
once-daily dosing in the evening resulted in a similar
improvement in pre-dose FEV1 to FF 200 mcg twice
daily. However, although FF 400 mcg once daily in the
morning resulted in a statistically and clinically signifi-
cant improvement in FEV1 compared with placebo, the
improvement was slightly less than that seen with FF
200 mcg twice daily. Both FF 200 mcg once-daily dosing
regimens did not increase the trough FEV1 by ≥ 200 ml,
vs. placebo after 8 weeks of dosing, though a ≥ 200 ml
change from baseline was observed with both regimens.
Although not powered to show equivalence between
the doses or scheduling of FF treatment, the results of
this study indicate that FF dosed at 400 mcg once-daily
in the evening resulted in similar efficacy to FF 200 mcg
dosed twice-daily. This was not the case for FF 400 mcg
dosed once-daily in the morning, where the point esti-
mate for the placebo adjusted change from baseline in
morning FEV1 was lower than the lower boundary for
the 95% confidence interval for the placebo adjusted
change from baseline in morning FEV1 seen with FF
200 mcg dosed twice-daily.
The findings from our trial are, in part, similar to
results from earlier double-blind studies evaluating
once-daily therapy with other ICS for asthma. In a 12-
week study, mometasone furoate 200 mcg administered
once daily in the evening was more effective than
mometasone furoate 200 mcg administered once daily
in the morning in terms of change in FEV1 and forced
vital capacity (FVC) [15]. Similar improvements in lung
function with evening compared with morning FF 400
Table 3 Most common on-treatment AEs (≥ 3% incidence in any treatment group) (ITT population)
Placebo (n = 101) FF dose
200 mcg OD/AM
(n = 105)
200 mcg OD/PM
(n = 103)
400 mcg OD/AM
(n = 111)
400 mcg OD/PM
(n = 113)
200 mcg
BD
(n = 113)
Any AE, n (%) 28 (28) 36 (34) 32 (31) 43 (39) 35 (31) 38 (34)
Headache 6 (6) 8 (8) 7 (7) 10 (9) 7 (6) 9 (8)
Nasopharyngitis 4 (4) 8 (8) 8 (8) 3 (3) 7 (6) 6 (5)
Bronchitis 2 (2) 1 (< 1) 3 (3) 4 (4) 4 (4) 0
Pharyngolaryngeal pain 1 (< 1) 2 (2) 3 (3) 2 (2) 1 (< 1) 3 (3)
Upper respiratory tract infection 2 (2) 3 (3) 2 (2) 2 (2) 1 (< 1) 1 (< 1)
Dysphonia 0 1 (< 1) 1 (< 1) 1 (< 1) 2 (2) 3 (3)
Rhinitis 0 4 (4) 1 (< 1) 0 1 (< 1) 2 (2)
Rhinitis allergic 1 (< 1) 2 (2) 3 (3) 0 0 1 (< 1)
Dizziness 0 3 (3) 0 2 (2) 1 (< 1) 0
Influenza 2 (2) 0 1 (< 1) 3 (3) 0 0
Pharyngitis 4 (4) 2 (2) 0 0 0 0
Respiratory tract infection 0 1 (< 1) 0 3 (3) 1 (< 1) 0
AE = adverse event; AM = morning dosing; BD = twice daily; OD = once daily; PM = evening dosing
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Figure 4 Adjusted treatment ratio for 24-hour urinary cortisol
excretion for each FF treatment group vs. placebo (UC
population). Error bars are 95% confidence intervals.
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mcg dosing were reported in our study. However, in the
once-daily mometasone furoate 200 mcg study, the
change from baseline in FEV1 and FVC with morning
dosing was not significantly different from placebo [15].
In contrast, our study demonstrated significant improve-
ments from baseline in FEV1 vs. placebo with both
morning and evening FF 200 mcg and FF 400 mcg
once-daily dosing. In a second study, budesonide 400
mcg administered once daily in the morning or evening
was as effective as budesonide 200 mcg administered
twice daily for 12 weeks. Mean differences between pla-
cebo and active treatments at weeks 11 and 12 were
higher for the 400 mcg once-daily evening regimen
compared with the morning regimen in terms of both
morning and evening PEF [13]. Similarly, ciclesonide
200 mcg once daily dosed in the evening compared with
morning dosing resulted in greater improvements in
morning (12-hour treatment) and evening (24-hour
treatment) PEF relative to baseline at 8 weeks [16].
However, more recent studies have reported that twice
daily dosing with 80 mcg ciclesonide is generally more
efficacious than once daily dosing with 160 mcg cicleso-
nide (in the morning) in improving and maintaining dis-
ease control, over treatment periods of 12-16 weeks
[25,26].
The duration of action of the majority of currently
available ICS necessitates twice-daily administration.
Only one ICS (mometasone furoate) is currently recom-
mended for once-daily dosing in both the US and Eur-
ope but only for use in patients with non-severe asthma
[2,27]. Thus, at present the potential advantages of once
daily dosing are not available for patients of all asthma
severities. Non adherence to treatment is an important
issue in asthma management, particularly in patients on
long-term ICS and other controller medications [2,28].
In a retrospective analysis of treatment adherence and
markers of asthma control in patients with mild asthma,
adherence (measured by percentage days covered) to
twice-daily ICS was just 14.5% [29]. Other studies have
shown that regular use of ICS is associated with a
reduction in hospitalization or emergency room visits
due to asthma [30,31]. Therefore, lack of adherence and
sub-optimal use of ICS therapy highlights the potential
benefits of a convenient once-daily ICS that provides
effective asthma control over a 24-hour period across a
broad spectrum of asthma patients.
In the current study, FF was generally well tolerated and
the incidence of AEs with FF was low and generally similar
to placebo; however, three cases of oedema leading to
withdrawal were reported with FF (one in each of three
different treatment groups). This study was not powered
for safety and these events will be assessed as we compile
more information during the drug development pro-
gramme. Data from other phase II studies evaluating FF
have reported similar safety findings with daily doses of up
to 600 mcg [20-22] as those reported here, save for no
withdrawals due to oedema. In these other studies, head-
ache, upper respiratory tract infection, oropharyngeal pain,
nasopharyngitis, and sinusitis were the most frequently
reported AEs and occurred with a similar incidence to pla-
cebo. The incidence of oral candidiasis was typically low at
< 1-4% [20-22]. At the moderate and high doses required
to treat some patients with asthma, ICS therapy can lead
to suppression of the HPA axis [32] and it has been sug-
gested that this effect may be accentuated by once-daily
dosing in the evening [33,34]. However, safety data from
our study suggest that FF 200 or 400 mcg administered
once daily in the evening has a minimal effect on UC
levels; 24-hour urinary excretion ratios were similar to pla-
cebo for all FF treatment groups and between morning
and evening dosing and once-daily and twice-daily dosing.
These data are consistent with previously published stu-
dies. One study showed no difference in placebo-adjusted
24-hour UC results for budesonide 400 mcg administered
once daily in the morning compared with evening [35]. In
another study, there was no significant difference in morn-
ing serum cortisol levels, between patients receiving
mometasone furoate dosed once-daily in the evening (1
inhalation of 400 mcg or 2 inhalations of 200 mcg) and
those receiving placebo, also in the evening [36]. In addi-
tion, phase II studies with FF have demonstrated similar
UC levels for different doses of FF given once daily in the
evening compared with placebo [20-22].
The design of the current study utilized pre-dose FEV1
as the primary endpoint because it is a reliable index of
24-hour duration of action and the study was adequately
powered to demonstrate treatment differences on this
basis. The inclusion of a placebo control group enabled
the magnitude of effect of FF on efficacy and safety
parameters to be established and also allowed variability
in 24-hour UC excretion values to be determined for
comparison against the active treatment groups. An 8-
week treatment period was selected as an appropriate
duration to observe changes in pulmonary function
from baseline and to permit assessment of differences
between treatments. A limitation of the study was that
it was not powered to demonstrate non-inferiority of
the once-daily treatment groups relative to the twice-
daily treatment group or of the morning dosing regi-
mens relative to the evening dosing regimens; therefore
statistical comparisons of all FF treatment groups were
only compared with placebo. Furthermore, as dosing
frequency can impact the efficacy of ICS therapy, parti-
cularly in patients with uncontrolled or severe asthma
[37], conclusions drawn from this population of patients
with mild to moderate asthma preclude generalizations
of efficacy and safety to patients with higher levels of
uncontrolled asthma and symptom severity.
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Conclusions
Once-daily treatment with FF 400 mcg dosed in the eve-
ning or morning showed clinically and statistically sig-
nificant improvements in pre-dose FEV1 (≥ 200 ml). FF
at both doses and all regimens was generally well toler-
ated. FF 400 mcg administered once daily in the evening
had similar efficacy to FF 200 mcg administered twice
daily. These findings suggest that FF is an effective and
well tolerated once-daily ICS, although additional confir-
matory studies are required.
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